Initial phase 1 clinical trials using the global HDAC inhibitor Panobinostat (NCT02717455), combined with RT in DIPG showed no improvement in progression free survival or overall survival, in part due to its limited patient tolerability [18]. This evidence concerns the gene HDAC9 and diffuse intrinsic pontine glioma.